Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Randomized phase II trial to compare the effectiveness of bortezomib with or without
gemcitabine in treating patients who have metastatic pancreatic cancer. Bortezomib may stop
the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used
in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining bortezomib with gemcitabine may kill more tumor cells.